Economic burden of hospital admissions for adverse drug reactions in France: The IATROSTAT‐ECO study

Aims Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR‐HA in France. Methods A partial economic evaluation from the viewpoint of French public...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:British journal of clinical pharmacology Ročník 91; číslo 2; s. 439 - 450
Hlavní autoři: Laroche, Marie‐Laure, Tarbouriech, Noémie, Jai, Taha, Valnet‐Rabier, Marie‐Blanche, Nerich, Virginie
Médium: Journal Article
Jazyk:angličtina
Vydáno: England John Wiley and Sons Inc 01.02.2025
Témata:
Adult
adverse drug reactions
Aged
Aged, 80 and over
cost analysis
Cost of Illness
Drug-Related Side Effects and Adverse Reactions - economics
Drug-Related Side Effects and Adverse Reactions - epidemiology
Female
France - epidemiology
hospitalization
Hospitalization - economics
Hospitalization - statistics & numerical data
Humans
Length of Stay - economics
Male
Middle Aged
observational study
Original
Pharmacovigilance
Retrospective Studies
Young Adult
France
adverse drug reactions
hospitalization
cost analysis
pharmacovigilance
observational study
ISSN:0306-5251, 1365-2125, 1365-2125
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Aims Hospitalizations for adverse drug reactions (ADR‐HA) have increased over the last decade, but the impact of ADR‐HA has rarely been evaluated. The aim of this study was to estimate the economic burden of ADR‐HA in France. Methods A partial economic evaluation from the viewpoint of French public health insurance was performed, based on a previous pharmacovigilance study (IATROSTAT) performed in 2018 in public hospital medical units. The cost included direct medical costs, collected retrospectively, from the French hospital discharge database. The economic burden was estimated by calculating the total cost per ADR‐HA patient (cost of hospital stays, additional daily cost of specific stays, such as in a resuscitation, intensive care or continuous surveillance unit, drug products and medical devices in addition to Healthcare Resource Group‐based tariffs, and specific outpatient consultations and other clinical and technical medical procedures, over 3 months as from the first day of ADR‐HA). The robustness of the results was assessed using a one‐way deterministic sensitivity analysis of cost factors applying tariffs from 2023 instead of 2018. Results According to the 2018 tariffs (vs. 2023), the mean total cost per patient with ADR‐HA was estimated at €5208 ± €3719 (vs. €5974 ± €4232) ranging from €514 to €23 355 (vs. €618 to €27 380). The total cost for 196 patients with ADR‐HA admitted to a sample of French public hospitals was estimated at €1 020 549 (vs. €1 170 960). It could be estimated at €1.3 billion at the national level. Conclusions In addition to the increase in the number of expensive drugs, the ageing population and polypharmacy, the economic impact of serious ADR‐HA weighs heavily on healthcare spending.
Bibliografie:The authors confirm that the Principal Investigator for this study is Professor Marie‐Laure Laroche.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0306-5251
1365-2125
1365-2125
DOI:10.1111/bcp.16266